Prevalence of Hypoglycaemia in Congenital Adrenal Insufficiency

Overview

Children with congenital primary and secondary adrenal insufficiency, who are deficient in cortisol, are at risk for hypoglycaemia, irrespective of appropriate hydrocortisone treatment, which can lead to potentially serious neurological complications. Few series are described in pediatrics. The prevalence of hypoglycaemia is probably underestimated because it is often asymptomatic and capillary blood glucose monitoring is not always performed routinely. The objective of the study is to evaluate the prevalence of hypoglycaemia in children with adrenal insufficiency.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 31, 2022

Detailed Description

Children with congenital primary and secondary adrenal insufficiency, who are deficient in cortisol, are at risk for hypoglycaemia, irrespective of appropriate hydrocortisone treatment, which can lead to potentially serious neurological complications. Few series are described in pediatrics. The prevalence of hypoglycaemia is underestimated because it is often asymptomatic and capillary blood glucose monitoring is not always performed routinely. The objective of the study is to evaluate the prevalence of hypoglycaemia in children with congenital adrenal insufficiency. The study will follow for one year children from 6 months to 6 years, with central and peripheral adrenal insufficiency. 4 study times are planned with two measurement methods: – Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals. – Measurement of capillary blood glucose, in the morning on an empty stomach, every first week of each month for 12 months, with Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the test strips Accu-Chek performed. – Measurement of capillary glycaemia in case of suspicion of hypoglycaemia. Measure left free according to the judgment of the parents of the necessary character or not. With Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek performa strips.

Interventions

  • Other: Continuous blood glucose measurement
    • Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
  • Other: Measurement of capillary blood glucose
    • Measurement of capillary blood glucose : In the morning on an empty stomach, every first week of each month for 12 months. In case of suspicion of hypoglycaemia (parental assessment). Abbott’s Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips.

Arms, Groups and Cohorts

  • Other: Adrenal insufficiency
    • Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of hypoglycaemia
    • Time Frame: 1 year
    • Number of hypoglycaemic events. Hypoglycaemia will be defined by a glucose level measured at a glucose level of less than or equal to 0.55 g /L (3 mmol /L).

Secondary Measures

  • Duration of hypoglycaemia
    • Time Frame: 1 year
    • Time in hypoglycaemia measured in minutes per day during the continuous blood glucose measurements.
  • Percentage of time in hypoglycaemia
    • Time Frame: 1 year
    • Percentage of time in hypoglycaemia during the continuous blood glucose measurements.
  • Glycemic variations rate
    • Time Frame: 1 year
    • Glycemic variations rate during the different measurements times: minimum rate, maximum rate, average, median. Each result will be expressed in g /L or in mmol /L. Each date will expressed by one day and for one week.
  • Circumstances of occurrence of hypoglycaemia
    • Time Frame: 1 year
    • Circumstances in which hypoglycaemia occurred : descriptive data by parents, symptomatic or not symptomatic hypoglycaemia, descriptive signs if they are presents.
  • Occurrence of medical events
    • Time Frame: 1 year
    • Events during the follow-up of the study: modification of treatment of hydrocortisone and fludrocortisone, re-sugaring expressed in number of sugar cubes ( by sugar cube = 20 gr of sugar) or type of sweet food given to the child, hospitalizations ( type and reason for hospitalization, cause of the decompensation).
  • Body Mass Index
    • Time Frame: 1 year
    • Body mass divided by the square of the body height expressed in units of kg/m2 : mass in kilograms and height in meters
  • Systolic and Diastolic Blood Pressure
    • Time Frame: 1 year
    • Expressed millimetre of mercury
  • Heart rate
    • Time Frame: 1 year
    • Number of beats per minute
  • Stade tanner
    • Time Frame: 1 year
    • stade tanner A1 to A5
  • Amount of salt consumed per day
    • Time Frame: 1 year
    • Number of grams per day
  • Cortisol at 8 a.m.
    • Time Frame: 1 year
    • microgram / deciliter
  • Cycle of 17-hydroxyprogesterone
    • Time Frame: 1 year
    • Nanomole per liter
  • Adreno CorticoTropic Hormone
    • Time Frame: 1 year
    • Nanogram per liter
  • 17-hydroxyprogesterone
    • Time Frame: 1 year
    • Nanomole per liter
  • Delta-4-Androstenedione
    • Time Frame: 1 year
    • Nanomole per liter
  • Testosterone
    • Time Frame: 1 year
    • Nanomole per liter
  • Ionogram
    • Time Frame: 1 year
    • Nanomole per liter
  • Renin
    • Time Frame: 1 year
    • picogram/milliliter

Participating in This Clinical Trial

Inclusion Criteria

  • All male and female patients, followed in the Paediatric Endocrinology Department at Necker Hospital, with congenital primary and secondary adrenal insufficiency. – Age between 6 months and 6 years. – Included in the social security system. – Parental consent and willingness to participate in this study: involves training and skills in the use of blood glucometers. Exclusion Criteria:

  • Patients with acquired adrenal insufficiency. – Patients with type 1 or type 2 diabetes. – Patients with somatotropic deficiency associated with adrenal insufficiency. – Refusal or impossibility to perform the glycaemic measurements according to the procedure of the study. – Not covered by the social security system.

Gender Eligibility: All

Minimum Age: 6 Months

Maximum Age: 6 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dinane Samara-Boustani, MD, Principal Investigator, Assistance Publique – Hôpitaux de Paris
    • Michel Polak, MD, PhD, Study Director, Assistance Publique – Hôpitaux de Paris

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.